pdufa.bio
Home › Decisions › BMY 2026-03-06

BMY FDA decision — Mar 6, 2026

✓ APPROVED

Bristol-Myers Squibb Company — Sotyktu (deucravacitinib) - (POETYK PsA-1) · Psoriatic Arthritis.

Run-up into the decision (T-120 → T+5)

PDUFA 3/6/26$62.37$42.69/19/25
Daily close, T-120 (9/19/25) through T+5. Run-up high $62.37 on 2/27/26, low $42.6 on 11/5/25 (T-120 to T-1). FDA decision 3/6/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-03-06
OutcomeApproved
Drug / candidateSotyktu (deucravacitinib) - (POETYK PsA-1)
CompanyBristol-Myers Squibb Company
120-day run-up (T-120→T-1)+31.5%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio